The SCHEDULES Act of 2026 requires the Department of Veterans Affairs to set a standard for how quickly veterans receive appointments after being referred for care, whether at a VA facility or through community providers. The VA must publish this standard in the Federal Register and on its website at least 30 days before implementing or changing it. The bill mandates quarterly reports to Congress detailing how many referrals meet the standard, broken down by care type and facility, along with an annual ranking of medical centers from best to worst in meeting the timing requirement. These reports must also include data on steps taken to improve care timeliness and estimates for full compliance. The legislation aims to increase transparency and accountability in scheduling appointments for veterans receiving care through the VA system.
This bill establishes a new Office of Novel Therapeutics within the Veterans Health Administration to prepare for the implementation of emerging mental health treatments, such as psychedelic-assisted therapies, that are currently under FDA review. The office will develop national clinical standards, create training programs for staff, and designate specific medical centers as centers of excellence to lead research and implementation efforts. It also requires the VA to submit an annual report to Congress on research activities, clinical outcomes, and workforce readiness, while coordinating with other federal agencies on regulatory and reimbursement issues. The legislation focuses on ensuring patient safety, maintaining evidence-based practices, and providing integrated care for veterans with conditions like PTSD, depression, and substance use disorders.
The INSULIN Act of 2026 requires health insurance plans to limit insulin copayments to $35 per 30-day supply starting in 2027, with plans choosing to cap costs at 25% of the negotiated price after 2028. The bill also mandates that pharmacy benefit managers pass all rebates and discounts related to insulin directly to health plans rather than retaining them. Additional provisions include measures to speed up the approval process for generic and biosimilar insulin products, establish a pilot program to provide affordable insulin to uninsured individuals in 10 states, and create a resource center and hotline to help uninsured people access assistance programs.
This bill creates two grant programs to help prevent suicide among individuals under 26 years old by funding health care and education initiatives. The first program provides up to $20 million to states, health departments, hospitals, and other organizations to train health care providers on identifying suicide risks, discussing firearm safety, and connecting at-risk individuals with support services. The second program allocates $10 million to medical and nursing schools to develop curricula on suicide prevention and safe firearm storage for health care professionals. Additionally, the bill authorizes the use of up to 15 percent of the first grant's funds to distribute secure gun storage devices at reduced or no cost to households with youth, along with counseling on their use. The Department of Health and Human Services will maintain an informational website and submit annual reports to Congress on the programs' progress through fiscal year 2030.
The Veteran Infection Prevention Act requires sterile processing technicians in the Veterans Health Administration to obtain certification from an accredited training institution within two years of their appointment, with some exceptions for entry-level positions. Current employees who are not yet certified will have two years from the bill's enactment to become certified, and those who choose to pursue certification will receive a scholarship to help cover training costs. In exchange for the scholarship, recipients must commit to two years of service with the Veterans Health Administration after receiving their certification. This legislation aims to improve infection prevention standards by ensuring all sterile processing technicians meet professional certification requirements.
This bill strengthens the Defense Production Act to prioritize securing medical supplies like drugs, devices, and biological products that are essential for national defense. It requires the President to develop and submit a strategy within 180 days that outlines how to diversify supply chains, reduce foreign dependency, and protect the U.S. medical supply system. The legislation also authorizes funding for domestic companies that produce critical components or materials needed to secure these supply chains. Additionally, the President must provide annual progress reports to Congress on the implementation of these measures until September 2029.
This bill directs the Secretary of Health and Human Services to conduct a study on access to multiple contraceptive methods at community health centers located in health care deserts. The study will examine barriers such as reimbursement, inventory stocking, provider training, and patient education, and will identify which centers receive funding under the Public Health Service Act. Within 180 days of enactment, the Secretary must submit a report to Congress detailing the study findings. The bill defines key terms including "women in need," "health care desert," and "range of contraceptive methods" to ensure clarity in the study's scope.
This bill directs the Secretary of State to create a strategy for international cooperation on developing medical products to fight infectious diseases and antibiotic-resistant pathogens. The plan would involve foreign governments, global organizations, and private companies to share resources and expertise for creating vaccines, treatments, and diagnostics. It aims to strengthen public health systems in partner countries to prevent outbreaks from spreading to the United States. The strategy must be submitted to Congress within 18 months and must ensure fair contributions from participating nations based on their budgets and technical capabilities. The bill focuses on aligning these efforts with existing U.S. pandemic preparedness plans and avoiding duplication of work.
This bill would allow certain oral contraceptive drugs to be sold over-the-counter to adults aged 18 and older by requiring the FDA to prioritize their review and waive associated application fees. It specifically excludes emergency contraceptives and drugs also approved for induced abortion from these provisions. The legislation also directs the Government Accountability Office to study how federal programs fund contraception over the past 15 years, covering Medicare, Medicaid, and other health services.
The Maternal Vaccination Act directs federal funding to expand a public health campaign focused on increasing vaccination rates among pregnant and postpartum individuals and their children. It modifies existing laws to include these groups in awareness efforts and specifically targets racial and ethnic minority communities to address equity gaps. The bill also adjusts the funding timeline and amount for the campaign, increasing the annual allocation from $15 million to $17 million for fiscal years 2027 through 2031. These changes aim to improve maternal and child health outcomes by ensuring broader access to vaccination information and resources.